Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lipocine (LPCN) stocks in Canada

Learn how to easily invest in Lipocine stocks.

Lipocine is a biotechnology business based in the US. Lipocine stocks (LPCN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.35 – a decrease of 10.53% over the previous week. Lipocine employs 13 staff and has a trailing 12-month revenue of around $54,994.

How to buy shares in Lipocine

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LPCN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lipocine stock price (NASDAQ:LPCN)

Use our graph to track the performance of LPCN stocks over time.

Lipocine shares at a glance

Information last updated 2022-01-18.
Latest market close$0.89
52-week range$0.93 - $2.42
50-day moving average $1.09
200-day moving average $1.24
Wall St. target price$3.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.22

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Lipocine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Lipocine price performance over time

Historical closes compared with the close of $0.8911 from 2022-01-21

1 week (2022-01-11) -12.64%
1 month (2021-12-22) -16.72%
3 months (2021-10-22) -15.93%
6 months (2021-07-22) -34.48%
1 year (2021-01-22) -60.04%
2 years (2020-01-22) 68.83%
3 years (2019-01-22) 1.56
5 years (2017-01-20) 3.37

Lipocine financials

Revenue TTM $54,994
Gross profit TTM $-5,053,695
Return on assets TTM -27.71%
Return on equity TTM -75.11%
Profit margin 0%
Book value $0.37
Market capitalisation $86.1 million

TTM: trailing 12 months

Lipocine share dividends

We're not expecting Lipocine to pay a dividend over the next 12 months.

Have Lipocine's shares ever split?

Lipocine's shares were split on a 1:100 basis on 24 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.

Lipocine share price volatility

Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.93 up to $2.42. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.3305. This would suggest that Lipocine's shares are less volatile than average (for this exchange).

Lipocine overview

Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site